公开(公告)号：EP2409976A1

公开(公告)日：2012-01-25

申请号：EP10753606.2

申请日：2010-03-19

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： YASUHARA, Akito ,  YAMAMOTO, Shuji ,  OHTA, Hiroshi ,  SHIRASAKI, Yoshihisa ,  SAKAGAMI, Kazunari ,  HAYASHI, Masato ,  SHIBATA, Tsuyoshi ,  SHIMAZAKI, Youichi ,  ARAKI, Yuko ,  ABE, Kumi ,  SUN, Xiang-Min

IPC分类号： C07D405/12 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4439 ,  A61P25/08 ,  A61P25/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D405/14 ,  C07D409/12 ,  C07D471/04

CPC分类号： C07D471/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12

摘要： The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder:

摘要翻译： 本发明旨在提供基于甘氨酸摄取抑制作用并可用于预防或治疗诸如精神分裂症，阿尔茨海默氏病，认知功能障碍，痴呆等的疾病的新型式[I]化合物或其药学上可接受的盐。 焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定恐惧症，急性应激障碍等），抑郁症，药物成瘾，痉挛，震颤和睡眠障碍：

公开(公告)号：EP2678349A1

公开(公告)日：2014-01-01

申请号：EP12749570.3

申请日：2012-02-20

申请人： Taisho Pharmaceutical Co., Ltd. ,  Meiji Seika Pharma Co., Ltd.

发明人： SUGIMOTO, Tomohiro ,  SASAMOTO, Naoki ,  KUROSAKA, Jun ,  HAYASHI, Masato ,  YAMAMOTO, Kanako ,  KASHIMURA, Masato ,  USHIKI, Yasunobu ,  OGITA, Haruhisa ,  MIURA, Tomoaki ,  KANEMOTO, Kenichi ,  KUMURA, Kou ,  YOSHIDA, Satoshi ,  TAMURA, Keiji ,  SHITARA, Eiki

IPC分类号： C07H17/08 ,  A61K31/7048 ,  A61P31/04

CPC分类号： C07H17/08

摘要： A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

公开(公告)号：EP2678349B1

公开(公告)日：2016-01-13

申请号：EP12749570.3

申请日：2012-02-20

申请人： Taisho Pharmaceutical Co., Ltd. ,  Meiji Seika Pharma Co., Ltd.

发明人： SUGIMOTO, Tomohiro ,  SASAMOTO, Naoki ,  KUROSAKA, Jun ,  HAYASHI, Masato ,  YAMAMOTO, Kanako ,  KASHIMURA, Masato ,  USHIKI, Yasunobu ,  OGITA, Haruhisa ,  MIURA, Tomoaki ,  KANEMOTO, Kenichi ,  KUMURA, Kou ,  YOSHIDA, Satoshi ,  TAMURA, Keiji ,  SHITARA, Eiki

IPC分类号： C07H17/08 ,  A61K31/7048 ,  A61P31/04

CPC分类号： C07H17/08

公开(公告)号：EP4056581A1

公开(公告)日：2022-09-14

申请号：EP20883820.1

申请日：2020-11-06

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： HAYASHI, Masato ,  TAKEUCHI, Tomoki ,  NOMURA, Yusaku ,  TAMITA, Tomoko ,  SHIMONO, Rie

IPC分类号： C07K7/06 ,  A61K38/07 ,  A61K38/08 ,  A61P35/00 ,  A61P43/00 ,  C12N9/99

摘要： The present invention provides a substituted polypeptide or a pharmaceutically acceptable salt thereof with an effect to inhibit MMP2, the substituted polypeptide represented by formula [I']:

公开(公告)号：EP2454240A1

公开(公告)日：2012-05-23

申请号：EP10799955.9

申请日：2010-07-15

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： YASUHARA, Akito ,  SAKAGAMI, Kazunari ,  OHTA, Hiroshi ,  HAYASHI, Masato ,  SHIRASAKI, Yoshihisa ,  YAMAMOTO, Shuji ,  SHIMAZAKI, Youichi ,  ARAKI, Yuko ,  ABE, Kumi ,  SUN, Xiang-Min

IPC分类号： C07D233/90 ,  A61K31/4164 ,  A61K31/4196 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D249/10

CPC分类号： C07D249/10

摘要： The present invention aims to provide novel compounds represented by formula [I] or pharmaceutically acceptable salts thereof: [Formula 1] which are useful for prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, convulsion, tremor, pain, or sleep disorders, based on their inhibitory effect against glycine uptake.

摘要翻译： 本发明的目的在于提供可用于预防或治疗精神分裂症，阿尔茨海默氏病，认知障碍，痴呆症，焦虑症（例如，精神分裂症， 广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定恐怖症，急性应激障碍），抑郁症，药物依赖性，惊厥，震颤，疼痛或睡眠障碍 抵抗甘氨酸摄取。

公开(公告)号：EP2098509A1

公开(公告)日：2009-09-09

申请号：EP07829299.2

申请日：2007-10-05

申请人： Taisho Pharmaceutical Co. Ltd.

发明人： SEKIGUCHI, Yoshinori ,  KANUMA, Kosuke ,  SAKAGAMI, Kazunari ,  HAYASHI, Masato ,  KASHIWA, Shuhei ,  OMODERA, Katsunori

IPC分类号： C07D211/58 ,  A61K31/4468 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P25/08 ,  A61P25/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

CPC分类号： C07D405/12 ,  C07D211/58 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D409/12

摘要： Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)

or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

摘要翻译： 本发明公开了一种药物组合物，其包含式（I）所示的化合物或其药学上可接受的盐作为活性成分，其对黑色素浓集激素受体具有拮抗活性。 由于其对MCH受体的拮抗活性，所述药物组合物用于预防或治疗疾病如抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症， 社交焦虑障碍），注意力缺陷障碍，躁狂症，躁狂抑郁症，精神分裂症，情绪障碍，压力，睡眠障碍，发作，记忆障碍，认知障碍，痴呆，遗忘症，deli妄，肥胖症，进食障碍，食欲不振， 贪食症，视力障碍，糖尿病，心血管疾病，高血压，血脂异常，心肌梗塞，运动障碍（例如帕金森病，癫痫，惊厥，震颤），药物滥用和药物成瘾。